• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of bone diseases and bone conditions associated with immunodeficiency or immunosuppression.
    公开号:BE1018578A5
    申请号:E2009/0287
    申请日:2009-05-07
    公开日:2011-04-05
    发明作者:Valentina Albarani；Enrico Bastianelli；Cindy Badoer
    申请人:Bone Therapeutics Sa；
    IPC主号:
    专利说明:

    HUMAN DOS-FORMING CELLS IN THE TREATMENT OF BONE CONDITIONS AND BONE DISEASES ASSOCIATED WITH IMMUNODEFICIENCY OR
    IMMUNOSUPPRESSION
    The invention relates to therapeutic applications of bone-forming cells in the treatment of bone diseases and conditions associated with immunodeficiency or immunosuppression.
    The present inventors have been surprised to realize that bone forming cells exhibit potent antigen presenting cell (APC) properties, in addition to expected osteoregenerative actions, and thus are useful in the treatment of diseases and disorders. states associated with immunodeficiency or immunosuppression.
    Advantageously, the inventors have also discovered that bone-forming cells, such as, in particular, bone-forming cells that can be obtained in vitro by differentiation from mesenchymal stem cells (MSCs) or cells stromal bone marrow (BMSC), may have distinctive immunological markers (such as, for example, HLA class II antigen) and antigen-presenting cell properties substantially independent of activation or stimulation ( such as, for example, interferon gamma). Thus, said APC markers and properties are not necessarily confined to a narrow time window as a result of activation or stimulation. Such comparatively constant APC properties make bone forming cells an advantageous agent in the treatment of the above diseases and conditions.
    Accordingly, in certain aspects the invention provides: isolated bone forming cells for use in the treatment of a disease or condition associated with immunodeficiency or immunosuppression; the use of bone-forming cells isolated for the manufacture of a medicament for the treatment of a disease or condition associated with immunodeficiency or immunosuppression; a method for preventing and / or treating a disease or condition associated with immunodeficiency or immunosuppression in a subject that requires such treatment, comprising administering to said subject a prophylactically or therapeutically effective amount of bone-forming cells isolated; a pharmaceutical composition comprising isolated bone forming cells for use in the treatment of a disease or condition associated with immunodeficiency or immunosuppression.
    The bone-forming cells may preferably be of animal origin, more preferably of mammalian origin, including a non-human mammal, and even more preferably of human origin.
    Bone forming cells can usually be obtained from or derived from a biological sample of a subject (i.e., a sample taken from a subject and including cells thereof) such as preferably a human subject or a non-human mammal subject.
    The bone-forming cells may preferably be employed for autologous administration (i.e., administered to the same subject from which the cells were obtained or derived) or allogeneic administration (i.e. administered to a subject different from that from which the cells were obtained or derived but of the same species). Xenogeneic administration of said bone-forming cells may also be possible (i.e. cells obtained or derived from a subject of one species are administered to a subject of a different species).
    Preferably, human bone forming cells should be used for autologous or allogeneic administration to human subjects having a disease or condition associated with immunodeficiency or immunosuppression.
    The term "bone forming cells" as used herein generally refers to cells capable of contributing to the formation of bone material and / or bone matrix and indicates cells or isolated cell populations that have progressed partially. or complete their progression along a path of osteogenic differentiation. Without limitation, bone forming cells include, in particular, osteoprogenitor, osteoblast, osteocyte and other types of osteogenic cell line as known in the art.
    Those skilled in the art thus generally appreciate the limitations of the term "bone forming cells" as intended herein. Nevertheless, by way of indication and not limitation, the present bone-forming cells may have any, several or all of the following characteristics: a) the cells comprise the expression of alkaline phosphatase (ALP) , more specifically alkaline phosphatase of the bone-liver-kidney type; b) the cells comprise the expression of any one or more of the following: aminoterminal propeptide of procollagen type 1 (P1NP), osteonectin (ON), osteopontin (OP), osteocalcin (OCN) and bone sialoprotein (BSP); c) the cells demonstrate an ability to mineralize external environments or to synthesize the calcium-containing extracellular matrix (eg, upon exposure to an osteogenic medium, see Jaiswal et al., 1997, J Cell Biochem 64: 295-312). The accumulation of calcium inside the cells and the deposition in the proteins of the matrix can be measured in a conventional manner, for example by culturing in 45Ca2 +, washing and re-culturing then by determining any radioactivity present in the cell. inside the cell or deposited in the extracellular matrix (US 5,972,703) or using an alizarin red mineralization assay (see, for example, Gregory et al 2004, Analytical Biochemistry 329: 77 -84); d) the cells do not substantially differentiate any, and preferably none, of cells of the adipocyte lineage (for example adipocytes) or of the chondrocyte line (for example chondrocytes). The lack of differentiation of such cell lines can be tested using standard differentiation-inducing conditions established in the art (see, for example, Pittenger et al. 1999, Science 284: 143-7), and assay methods ( for example, during activation, the adipocytes typically stain with O-red oil showing an accumulation of lipids, the chondrocytes typically stain with alcian blue or safranin O). The marked lack of propensity for adipogenic and / or chondrogenic differentiation can typically mean that less than 50%, or less than 30%, or less than 5%, or less than 1% of the cells tested would show signs of adipogenic or chondrogenic differentiation when applied to the respective test.
    In one embodiment, the bone-forming cells may have all of the features listed in a), c) and d) above.
    In one embodiment, the bone-forming cells are positive for (i.e. they include expression of) HLA class II antigens.
    In one embodiment, the bone-forming cells are positive for (i.e. they include expression of) HLA class I and HLA class II antigens.
    In another embodiment, the bone-forming cells demonstrate antigen presenting cell (APC) properties.
    In another embodiment, the bone-forming cells can demonstrate immunosuppressive properties.
    Isolated bone forming cells or cell populations for use in the invention may be obtained or derived from any suitable manner known in the art. Without limitation, an appropriate method for obtaining bone-forming osteoblasts, more particularly osteoblasts and HLA class II-positive osteoblast populations, has been described in WO 2007/093431 and involves the implementation of cultured bone marrow stromal cells (BMSC) or mesenchymal stem cells (MSC) isolated in the presence of serum or plasma and basic fibroblast growth factor (FGF-2). In another example, bone-forming osteoblasts, more particularly HLA class II-positive osteoblasts, can be isolated and cultured directly from trabecular bone as described by Skjodt et al 1985 (J Endocrinol 105). : 391-6). In yet another example, the cells of the osteogenic lines can be obtained by differentiation of MSCs in an osteogenic medium as described by Pittenger et al 1999 (Science 284: 143-7) and Jaiswal et al 1997 (supra), preferably in presence of FGF-2 to obtain osteoblasts and HLA class II-positive osteoblast populations.
    In a preferred embodiment, the isolated bone forming cells for use as defined herein may be obtained or directly obtained by differentiation from BMSCs or MSCs. Advantageously, such differentiation may include exposure of BMSCs or MSCs to FGF-2 to obtain osteoblasts or HLA class II-positive osteoblast populations. These cells exhibit comparatively stable APC properties that can be obtained without external activation factors.
    The term "immunodeficiency" generally indicates a state in which a specific and / or non-specific immune system function of a subject is pathologically or absent reduced. Diseases or conditions associated with immunodeficiency or "immunodeficiency disorders" refers to a diverse group of conditions characterized primarily by increased susceptibility to various opportunistic infections resulting in acute, recurrent or chronic severe illness resulting immunodeficiency due to one or more immune system failures. Immunodeficiency disorders include, but are not limited to, "immunodeficiency syndromes" in which all features are the result of immune failure, and "immunodeficiency syndromes", in which certain characteristics, even important ones, can not be explained by immune failure.
    The group of immunodeficiency disorders also includes diseases and conditions associated with immunosuppression, the latter term referring to artificially controlled artificial reduction or prevention of a subject's immune response. Immunosuppression in subjects may be caused by immunosuppressants ("immunosuppressive" refers to any component or agent known or whose ability to suppress or prevent an undesired immune response, such as rejection by the immune system of a transplanted organ, examples of immunosuppressants include, without limitation, cyclosporin A, mycophenolate mofetil, rapamycin, FK506 and corticosteroids), or it may be in the form of a Side effect of therapy with other indications (eg, a side effect of chemotherapy for cancer).
    By way of example and not limitation, diseases and conditions associated with immunodeficiency or immunosuppression include: infection with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS), hypogammaglobulinemia, hematologic cancers such as leukemia and lymphoma, total removal of bone marrow, bone marrow transplantation, organ transplantation, lymphocytopenia (lymphopenia) of any origin, lupus erythematous, cachexia, opioid abuse, mastocytosis, rheumatic fever, trypanosomiasis, alcohol abuse; and treatments with: chemotherapeutic agents, corticosteroids, anti-TNF drugs, rays, immunosuppressive drugs such as, but not limited to, tacrolimus, cyclosporine, methotrexate, mycophenolate, azathioprine, interferons and immunoglobulins such as anti-CD20 and anti-CD3.
    In one embodiment, diseases or conditions associated with immunodeficiency or immunosuppression may also include an element of bone dysfunction or bone lesion (such as, for example, osteoporosis, osteonecrosis, osteopenia, bone fragility , bone necrosis, bone fracture (or microfractures), bone sclerosis and bone osteolysis). Advantageously, the bone-forming cells of the invention can act synergistically on such diseases by improving immunodeficiency and stimulating bone reconstruction.
    Therefore, in its embodiments the invention also provides: isolated bone forming cells for use in the treatment of bone disease or bone condition associated with immunodeficiency or immunosuppression; the use of bone-forming cells isolated for the manufacture of a medicament for the treatment of bone disease or bone condition associated with immunodeficiency or immunosuppression; a method of preventing and / or treating a bone disease or bone condition associated with immunodeficiency or immunosuppression in a subject that requires such treatment, comprising administering to said subject a prophylactically or therapeutically effective amount effective isolated bone forming cells; a pharmaceutical composition comprising isolated bone forming cells for use in the treatment of bone disease or bone condition associated with immunodeficiency or immunosuppression.
    Preferably, human bone forming cells may be employed for autologous or allogeneic administration to human subjects having bone disease or bone condition associated with immunodeficiency or immunosuppression.
    Isolated bone-forming cells may be administered to subjects for the treatment of diseases or conditions associated with immunodeficiency or immunosuppression, including bone diseases or bone conditions associated with immunodeficiency or immunosuppression, as defined above.
    Optionally, to stimulate the APC properties of the bone-forming cells, the cells may be treated with a pro-inflammatory cytokine prior to administration, or alternatively may be administered together with (eg simultaneously, sequentially or separately in any order) a pro-inflammatory cytokine. Examples of pro-inflammatory cytokines include without limitation IFNγ, TNFα, IL-1β, IL-17, IL-18.
    The treatment may employ autogenous (ie cells derived from the subject to be treated) cells and cell-forming populations, allogeneic (i.e., cells derived from one or more subjects different from the subject to be treated but belonging to the same species) or xenogeneic (that is to say cells derived from one or more subjects belonging to a species different from that of the subject to be treated) as defined above.
    Treatments of human subjects using autologous or allogenic human bone forming cells or cell populations as defined herein are in particular contemplated.
    Suitably, the bone forming cells and cell populations defined herein can be formulated into and administered as pharmaceutical compositions.
    The pharmaceutical compositions typically include bone forming cells or cell populations as an active ingredient and one or more pharmaceutically acceptable carriers / excipients.
    In another aspect, the invention relates to an arrangement comprising a surgical instrument for administering a composition to a subject, such as, for example, systemically, topically or at a site of bone lesion, and comprising in addition the cells or cell populations of the invention, or a pharmaceutical composition comprising said cells or cell populations, the arrangement being adapted for the administration of the pharmaceutical composition for example systemically, topically or at the site of injury bone. For example, a suitable surgical instrument may be capable of injecting a liquid composition comprising cells of the present invention, systemically, topically or at the bone lesion site.
    The cells or cell populations may be administered in a manner that allows them to graft or migrate to the intended tissue site and reconstitute or regenerate the functionally deficient area. For example, the cells may be administered at a site of musculoskeletal injury. For example, osteogenesis may be facilitated in accordance with a surgical procedure to reshape a tissue or insert a duplication or prosthetic device such as a hip replacement. In other circumstances, invasive surgery is not required and the composition may be administered by injection or (for example, for spinal repair) using a guide endoscope.
    In one embodiment, the pharmaceutical cell preparation as defined above may be administered in the form of a liquid composition. In embodiments, the cells or pharmaceutical composition comprising these can be administered systemically, topically or at a site of injury.
    In another embodiment, the cells or cell populations may be transferred to and / or cultured on a suitable substrate to provide implants. The substrate on which the cells can be applied and cultured may be a metal, such as titanium, a cobalt / chromium alloy or stainless steel, a bioactive surface such as calcium phosphate, polymeric surfaces such as polyethylene and the like. Although less preferred, a siliceous material such as glass-ceramic may be used as a substrate. Metals, such as titanium, and calcium phosphates, even though calcium phosphate is not an indispensable component of the substrate, are most preferred. The substrate may be porous or non-porous.
    For example, cells which have proliferated, or which are differentiated in culture dishes, can be transferred to solid three-dimensional supports in order to induce their multiplication and / or continuation of the differentiation process by incubating the solid support in a medium liquid nutrient of the invention, if necessary. The cells may be transferred to a solid three-dimensional support, for example by impregnating said support with a liquid suspension containing said cells. The impregnated supports obtained in this way can be implanted in a human subject. Such impregnated supports may also be re-cultured by being immersed in a liquid culture medium, before their final implantation.
    The solid three-dimensional support must be biocompatible so as to enable it to be implanted in a human. It can also be of any suitable form, such as a cylinder, a sphere, a plate or an arbitrarily shaped element. Of the materials suitable for the biocompatible three-dimensional solid support, particular mention may be made of calcium carbonate, and in particular aragonite, specifically in the form of coral skeleton, porous ceramic based on alumina, zirconia, phosphate tricalcium and / or hydroxyapatite, the imitation coral skeleton that is obtained by hydrothermal exchange to transform calcium carbonate into hydroxyapatite, or otherwise glass-ceramic apatite-wollastonite, bioactive glass-ceramics such as Bioglass ™ glasses.
    Examples
    Human Clinical Efficacy Data Study Design and Patient Populations
    A small randomized controlled trial was conducted in which eight patients with a severe condition associated with immunodeficiency or immunosuppression (ie, stage I or II femoral head osteonecrosis) were treated by nucleus decompression associated with implantation at the lesion site of either bone-forming cells with APC characteristics as obtained above (APC-OB, patients 4-8) or a population mesenchymal stromal cells derived from the bone marrow (control treatment, CTRL, patients 1-4).
    In these patients, chronic immunosuppression was due to high oral doses of corticosteroids for organ transplantation, autoimmune disease, or severe asthma.
    The efficacy of the treatment was investigated using both clinical (pain and hip function as measured using EVA visual scale and WOMAC ™ index, respectively) and radiological criteria. (Evidence of the progression of the X and MRI fracture stages III or IV, according to the ARCO classification for osteonecrosis). Patients were systematically evaluated and followed for 24 months.
    Results of the study 1. Clinical symptoms 1.1 Pain
    Overall, a decrease in pain was observed in the APC-OB group after 12 to 24 months compared to the CTRL group.
    In the APC-OB group, mean pain scores, as assessed by VAS, increased from 45.5 (± 23) initially to 16.3 (± 14) at three months, 17 8 (± 15) at six months, 15 (± 11 days at twelve months, 16.8 (± 11) at eighteen months, and 7.8 (± 12) at twenty-four months. Average pain scores were observed in the CTRL group, from 49 (± 32) initially to 60.5 (± 30.7) and 58.5 (± 18) at eighteen months and twenty-four months, respectively.
    Over time, the benefits of APC-OB treatment result in differences greater than 100% between the two groups at twenty-four months.
    1.2 Operational scores
    Similarly, in the APC-OB group, the mean WOMAC ™ index fell from 48 (+ 25) initially to 17.8 (± 23) at three months, 20.5 (± 24) to six months, 15.5 (± 12) to twelve months, 18 (± 11) to eighteen months and 18 (± 8) to twenty-four months. In contrast, the WOMAC ™ index deteriorated in the CTRL group over the same period, from 39.8 (± 25) initially to 56.8 (± 22) and 57 (± 26) to ten Eight and twenty-four months, respectively.
    Over time, the benefits of APC-OB treatment result in differences greater than 100% between the two groups at twenty-four months.
    1.3 Radiological progression At 24 months, the survival analysis showed that 75% of the bone lesions in the CTRL group had deteriorated to none in the APC-OB group.
    In addition, in the CTRL group the mean radiological score deteriorated from 1.3 at baseline to 2-3 months, 2.5 to 6 months, 2.8 to 12 months, 3 to 18 months and 25 months. four months. In comparison, patients treated with APC-OB showed only a minimal increase in mean radiological scores, from 1.5 at baseline to 1.5, 1.8 and 1.8 at twelve, eighteen and twenty-four months, respectively.
    conclusions
    In conclusion, our data indicate that patients (with osteonecrosis of the femoral head stage I or II related to corticosteroid-induced immunosuppression) receiving treatment with bone-forming cells with APC characteristics have shown improvement. pronounced clinical and radiological criteria compared to the control group.
    权利要求:
    Claims (9)
    [1]
    1. Isolated bone-forming cells for use in the treatment of bone disease or bone condition associated with immunodeficiency or immunosuppression, said bone-forming cells being osteoprogenitor, osteoblast, osteocyte or cells of the osteogenic line and said bone-forming cells comprising expression of HLA-II.
    [2]
    2. Isolated bone-forming cells for use according to claim 1, the bone-forming cells having the following characteristics: a) the cells comprise the expression of alkaline phosphatase (ALP); b) the cells comprise the expression of any one or more of the following: aminoterminal propeptide of procollagen type 1 (P1NP), osteonectin (ON), osteopontin (OP), osteocalcin (OCN) and bone sialoprotein (BSP) ; c) the cells demonstrate an ability to mineralize outdoor environments or to synthesize extracellular matrix containing calcium; d) the cells comprise the expression of HLA-I and HLA-II.
    [3]
    3. Isolated bone-forming cells for use according to any one of claims 1 or 2, wherein said bone-forming cells can be obtained by differentiation from mesenchymal stem cells (MSC) or marrow stromal cells. bone (BMSC).
    [4]
    4. Isolated bone-forming cells for use according to any one of claims 1 to 3, said bone-forming cells exhibiting antigen presenting properties.
    [5]
    5. Isolated bone-forming cells for use according to any one of claims 1 to 4, the bone-forming cells being of human origin and the medicament to be used for autologous or allogeneic administration to human subjects .
    [6]
    6. Isolated bone-forming cells for use according to any one of claims 1 to 5, said bone disease or bone condition associated with immunodeficiency or immunosuppression being osteoporosis, osteonecrosis, osteopenia, bone fragility, bone necrosis, bone fracture (or microfractures), bone sclerosis and bone osteolysis.
    [7]
    A pharmaceutical composition comprising bone forming cells and a pro-inflammatory cytokine for simultaneous, sequential or separate use in the treatment of bone disease or bone condition associated with immunodeficiency or immunosuppression .
    [8]
    The pharmaceutical composition for use according to claim 7, wherein the bone-forming cells comprise the expression of HLA-II.
    [9]
    A pharmaceutical composition for use according to any one of claims 7 or 8, the pro-inflammatory cytokine being IFNγ, TNFα, IL-1β, IL-17 or IL-18.
    类似技术:
    公开号 | 公开日 | 专利标题
    Liu et al.2014|The effect of simvastatin on chemotactic capability of SDF-1α and the promotion of bone regeneration
    JP6598823B2|2019-10-30|Human osteogenic cells in the treatment of conditions and bone diseases associated with immunodeficiency or immunosuppression
    CA2211120C|2001-04-03|Lineage-directed induction of human mesenchymal stem cell differentiation
    BE1018748A3|2011-08-02|NOVEL MESENCHYMAL STEM CELLS AND OSTEOGENIC CELLS.
    McAllister et al.2009|Histologic Evaluation of a Stem Cell–Based Sinus‐Augmentation Procedure
    Ohgushi et al.2003|Mesenchymal stem cells and bioceramics: strategies to regenerate the skeleton
    Duarte et al.2001|The effect of an immunosuppressive therapy and its withdrawal on bone healing around titanium implants. A histometric study in rabbits
    de Freitas et al.2016|Histological analysis and gene expression profile following augmentation of the anterior maxilla using rh BMP‐2/ACS versus autogenous bone graft
    US20200032212A1|2020-01-30|Human Bone-Forming Cells in the Treatment of Inflammatory Rheumatic Diseases
    Iguchi et al.2017|Effect of local bone marrow stromal cell administration on ligature-induced periodontitis in mice
    Huang et al.2006|Osteoblastic differentiation of rabbit mesenchymal stem cells loaded in A carrier system of Pluronic F127 and Interpore
    Beger et al.2018|Biofunctionalization of synthetic bone substitutes with angiogenic stem cells: influence on regeneration of critical-size bone defects in an in vivo murine model
    Kaihara et al.2002|Effect of FK506 on osteoinduction by recombinant human bone morphogenetic protein-2
    Bohlouli et al.2020|Effect of Vitamin K2 as A Stimulants of Bone Regeneration in Osteoporosis Therapy
    Glowacki2015|Treating Periodontal Disease Through the Recruitment and Expansion of Endogenous Regulatory T Cells
    Mesgarzadeh et al.2021|Evaluation of bone regeneration in mandible large defect using undifferentiated adipose stem cells loaded on gelatin carrier: An animal model case study
    BE1020528A3|2013-12-03|USES OF THE GROWTH AND DIFFERENTIATION FACTOR 8 |.
    Erdoğmuş et al.2021|The effect of mesenchymal stem cells, demineralized bone graft and platelet-rich plasma on osteogenesis in rat tibia defects
    WO2020060520A9|2020-06-11|Isolated septal cartilage exosome used for generating cartilage tissue
    Sauerbier et al.2013|Stem Cell-Based
    Laura et al.2009|SMOKING AND SALIVARY ANTIOXIDANT CAPACITY
    Mahmoud et al.2013|Evaluation of the Role of Bone Marrow-Derived Mesenchymal Stem Cells in Bone Regeneration of Dental Socket in Streptozotocin-Induced Diabetic Albino Rats.
    Chung2011|Cellular and molecular mechanisms involved in bony tissue repair of injured growth plate cartilage in rats.
    同族专利:
    公开号 | 公开日
    EP2297304B1|2017-09-13|
    JP2011519900A|2011-07-14|
    JP2015110009A|2015-06-18|
    CA2722803A1|2009-11-12|
    KR101687031B1|2016-12-15|
    AU2009245760A1|2009-11-12|
    US20110064692A1|2011-03-17|
    EP2297304A1|2011-03-23|
    DK2297304T3|2017-11-06|
    JP2017222662A|2017-12-21|
    KR20110013452A|2011-02-09|
    CN102016010A|2011-04-13|
    PT2297304T|2017-10-27|
    AU2009245760B2|2014-11-20|
    PL2297304T3|2018-01-31|
    US20150164951A1|2015-06-18|
    WO2009135914A1|2009-11-12|
    ES2649337T3|2018-01-11|
    JP6598823B2|2019-10-30|
    NO2297304T3|2018-02-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2007093431A1|2006-02-16|2007-08-23|Universite Libre De Bruxelles|A method for osteogenic differentiation of bone marrow stem cells and uses thereof|
    US5972703A|1994-08-12|1999-10-26|The Regents Of The University Of Michigan|Bone precursor cells: compositions and methods|
    GB0209896D0|2002-04-30|2002-06-05|Molmed Spa|Conjugate|
    WO2004035132A2|2002-10-15|2004-04-29|Irm Llc|Compositions and methods for inducing osteogenesis|
    US7951592B2|2003-11-10|2011-05-31|The Scripps Research Institute|Compositions and methods for inducing cell dedifferentiation|
    CA2722803A1|2008-05-07|2009-11-12|Bone Therapeutics S.A.|Human bone-forming cells in the treatment of conditions and bone diseases associated with immunodeficiency or immunosuppression|CA2722803A1|2008-05-07|2009-11-12|Bone Therapeutics S.A.|Human bone-forming cells in the treatment of conditions and bone diseases associated with immunodeficiency or immunosuppression|
    WO2013033777A1|2011-09-09|2013-03-14|Mesoblast, Inc|Methods for increasing osteoblastic function|
    US9486483B2|2013-10-18|2016-11-08|Globus Medical, Inc.|Bone grafts including osteogenic stem cells, and methods relating to the same|
    CN107714726A|2017-10-16|2018-02-23|中国科学院广州生物医药与健康研究院|A kind of method for remolding bone marrow microenvironment|
    CN110317271B|2019-07-02|2021-04-30|武汉云克隆科技股份有限公司|Heavy/light chain variable region of PINP recombinant antibody, coding gene and recombinant antibody|
    法律状态:
    2020-02-05| MM| Lapsed because of non-payment of the annual fee|Effective date: 20190531 |
    优先权:
    申请号 | 申请日 | 专利标题
    EP08155768|2008-05-07|
    EP08155768|2008-05-07|
    [返回顶部]